EUVIMEDEUVIMED entdecken
Crossref

Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO

Maxime Borgeaud, Annapaola Mariniello, Alfredo Addeo

Journal of Clinical Oncology · 20.11.2026

DOI: 10.1200/jco-26-02424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 20.11.2026. Verfasst von Maxime Borgeaud und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Borgeaud, M., Mariniello, A., & Addeo, A. (2026). Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-02424

Vancouver

Borgeaud M, Mariniello A, Addeo A. Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-02424

BibTeX
@article{Borgeaud2026,
  author = {Borgeaud, Maxime and Mariniello, Annapaola and Addeo, Alfredo},
  title = {Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-02424}
}
Kostenlos starten →